Ouyang M, Garnett AT, Han TM, et al. A web based resource characterizing the zebrafish developmental profile of over 16,000 transcripts. Gene Expr Patterns 2008;8:171–180.
98.
Romagnani S. Human Th17 cells. Arthritis Res Ther 2008;10: 206.
99.
Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18–32.
100.
Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389–400.
101.
Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, eds. Practical gynecologic oncology, 2nd ed. Baltimore, MD: Williams & Wilkins, 1994:327–375.
102.
Gotlieb WH, Abrams JS, Watson JM, et al. Presence of IL-10 in the ascites of patients with ovarian and other intraabdominal cancers. Cytokine 1992;4:385–390.
103.
Watson JM, Gotlieb WH, Abrams JH, et al. Cytokine profiles in ascitic ﬂuid from patients with ovarian cancer: relationship to levels of acute phase proteins and immunoglobulins, immunosuppression and tumor classification. J Soc Gynecol Invest 1993;186:8.
104.
Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod 1984;3:501–511.
105.
Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2–activated lymphocytes. Annu Rev Immunol 1986;4:681–709.
106.
Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–1492.
107.
Cappuccini F, Yamamoto RS, DiSaia PJ, et al. Identification of tumor necrosis factor and lymphotoxin blocking factor(s) in the ascites of patients with advanced and recurrent ovarian cancer. Lymphokine Cytokine Res 1991;10:225–229.
108.
Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the
David L. Olive Steven F. Palter
The female reproductive process involves the central nervous system (primarily hypothalamus), the pituitary gland, the ovary, and the uterus (endometrium). All must function appropriately for normal reproduction to occur.
Hypothalamic gonadotropin-releasing hormone (GnRH) simultaneously regulates both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in the pituitary by being secreted in a pulsatile manner. The pulse frequency determines the relative amounts of LH and FSH secretion.